Scopio Labs Closes $16 Million Series B Round to Expand Commercial Rollout of Automated Microscopy Solutions

All-Digital AI-Powered Platform to Reduce Human Error, Connect Remote Experts, Increase Diagnostic Lab Reliability and Efficiency

April 28, 2020

Scopio Labs, an advanced digital microscopy company, today announced it has completed a $16 million financing round, bringing its total funding to $30 million. The Series B round will enable Scopio Labs to expand commercial operations across human and veterinary care in the United States and Europe, by ramping up manufacturing and sales, and further developing a robust clinical trial pipeline to broaden its portfolio of offerings.

Scopio Labs is propelling microscopy into the digital age. Its platform automates the imaging of full microscopy samples into uniquely high-resolution digital scans using cutting-edge computational photography techniques. Scopio also built and integrated end-to-end AI and remote consultation solutions for large and small labs and hospitals across the continuum of care to improve diagnostic processes while reducing turn-around time.

“We are delighted by the additional investor support that reinforces our vision and dedication to advancing clinical and research fields into new arenas through microscopy, a cornerstone of science and medicine which has been held back from joining the digital revolution by the complexity of scanning samples easily and at such high resolution,” said Itai Hayut, co-founder and CEO at Scopio Labs.

Olive Tree Ventures led the Series B funding round. Other investors include Aurum VenturesOurCrowd, LR group and others. The closing of the funding round follows the company’s receipt of a CE mark certification for its X100 Full Field Peripheral Blood Smear (PBS) microscopy system, an all-in-one automated in-vitro hematology diagnostic platform that enables remote consultation and includes a computer-vision based decision support system. In addition, A multi-center study in preparation of an FDA submission is being completed. Earlier this year, the company launched ScopioVet, an end-to-end digital cytology solution for veterinary professionals.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Kazia has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 4,444,445 ADSs. The warrants will have an exercise price of $0.583 per ADS, will be immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about December 5, 2023, subject to the satisfaction of customary closing conditions.
The groundbreaking ColoSeal System™ enables minimally invasive colorectal tumor removal, eliminating the need for 2 open surgeries in today's standard of care notes Savage Medical.
Alto Neuroscience advises the funds will be used to support ongoing and planned late-stage clinical development of CNS product candidates with four Phase 2 readouts expected across the next 12-18 month
Micron Biomedical has received this grant from the Bill & Melinda Gates Foundation to fund mass production of needle-free vaccines utilizing Micron technology to expand the accessibility of measles-rubella vaccine in developing countries
Ann Lin, co-founder and CEO of Cromatic said, "Outsourcing R&D is one of the most powerful ways for innovative biotech companies to get off the ground. While founders of tech giants like Apple and Google could build their products in garages with minimal resources, founders in biotech are confronted with the capital expense of lab space and equipment and the lengthy process of building the right team before they can even test their ideas. That’s why we are building the most powerful R&D outsourcing platform for biotechs, so that scientists will have clarity, confidence and choice when evaluating and managing their service providers. Ultimately, we want to enable biotech companies to start in garages, just like tech giants.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy